Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236669 | 0.87 | ALDH1A1 (0.50) | ALDH1A1POLB | |
| SCHEMBL26098509 | 0.86 | DAO (0.46) | HTR2AALDH1A1POLB | |
| SCHEMBL2949018 | 0.86 | POLB (0.44) | HTR2AALDH1A1POLB | |
| SCHEMBL3946253 | 0.84 | HTR2A (0.44) | HTR2A | |
| SCHEMBL26711932 | 0.84 | HTR2A (0.41) | HTR2AALDH1A1POLBKCNH2 | |
| SCHEMBL22662833 | 0.83 | SMN1; SMN2 (0.53) | ALDH1A1POLB | |
| SCHEMBL8406068 | 0.82 | ALOX15 (0.48) | HTR2AALDH1A1POLB | |
| SCHEMBL21975820 | 0.82 | HTR2A (0.41) | HTR2A | |
| SCHEMBL4180905 | 0.82 | HTR2A (0.40) | HTR2AALDH1A1POLB | |
| SCHEMBL24530426 | 0.80 | HTR2A (0.39) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | HTR2A 2608/4885HTR2C 2765/4885ALDH1A1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.